Last updated on February 2018

Chidamide Plus DCAG for Relapsed/Refractory AML


Brief description of study

Despite advances in understanding the complexities of acute myeloid leukaemia (AML), the treatment of refractory or relapsed AML (rrAML) remains a daunting clinical challenge.The investigators designed a new regimen, including chidamide, decitabine, aclarubincin, cytarabine and G-CSF, to treat rrAML.

Clinical Study Identifier: NCT02886559

Find a site near you

Start Over